VTX002 for Colitis, Ulcerative

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Colitis, Ulcerative+2 More
VTX002 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it's safe and effective in treating moderate to severe ulcerative colitis. Up to 180 participants will be given the new drug daily for 28 days to 13 weeks, and then followed for up to 36 months.

Eligible Conditions
  • Colitis, Ulcerative

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Colitis, Ulcerative

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Day 1 of Induction Treatment Period to week 13

Week 13
Endoscopic improvement at Week 13
Histologic remission at Week 13
Mucosal Healing at Week 13
Symptomatic remission at Week 13
Week 13
Clinical remission at 13 weeks

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Colitis, Ulcerative

Trial Design

3 Treatment Groups

VTX002 Dose A
1 of 3
VTX002 Dose B
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group

180 Total Participants · 3 Treatment Groups

Primary Treatment: VTX002 · Has Placebo Group · Phase 2

VTX002 Dose A
Drug
Experimental Group · 1 Intervention: VTX002 · Intervention Types: Drug
VTX002 Dose B
Drug
Experimental Group · 1 Intervention: VTX002 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 of induction treatment period to week 13

Who is running the clinical trial?

Oppilan Pharma LtdLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Snehal U Naik, PhDStudy DirectorVentyx Biosciences, Inc

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
A person who has active UC is confirmed by endoscopy
Someone who has UC for more than three months is automatically screened for the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.